Oncoinvent, a clinical-stage radiopharmaceutical company based in Oslo, Norway, announced that its Phase 2 trial of Radspherin® has reached 50 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE